•  
  •  
  •  
  •  

2026-05-22 21:52:50

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Kolte-Patil Developers Ltd. Q4 & FY26 Financial Results
  • PNC Infratech Limited receives Rs. 228.90 crores based on settlement agreement from NHAI
  • NIS Management Ltd receives 5 work orders worth Rs. 30.77 crores
  • MAS Financial Services Ltd raises ₹360 Crore through NCD from FMO, the Dutch Entrepreneurial Development Bank
  • Aptus Pharma Ltd initiates brand promotion at Rajkot Hirasar Airport

Keywords Selected:  Biosimilar

Stock Report

  • Dr. Reddy's Laboratories Announces Launch of Oral Semaglutide Biosimilar 'Obeda®' (tablets) in India
  • Lupin receives European Commission approval for Biosimilar Ranibizumab
  • Zydus launches biosimilar Aflibercept 2 mg ANYRA™ for advancing ophthalmic care
  • Biocon Biologics Secures Full Global Rights to Biosimilar Adalimumab through Expanded FKB In-Licensing Agreement
  • Lupin receives Positive CHMP Opinion for Biosimilar Ranibizumab
  • Biocon Biologics Signs Settlement and License Agreement to Commercialize Biosimilar Aflibercept Worldwide
  • Lupin and Valorum Enter into an Exclusive Licensing Agreement for Biosimilar Armlupeg™ in the United States
  • Lupin and Zentiva Sign License and Supply Agreement for Commercializing Certolizumab
  • Lupin Ltd enters into agreement with Zentiva for biosimilar Certolizumab Pegol
  • CuraTeQ Biologics receives positive opinion for biosimilar Dazublys® from EMA
  • Biocon Biologics secures Market Entry Date for Yesafili™, an Interchangeable Biosimilar to Eylea®, in the U.S.
  • Biocon Biologics announces U.S. FDA Approval for Jobevne™, Biosimilar Bevacizumab, Expanding Its Oncology Portfolio
  • European Commission approves Biocon Biologics' Ustekinumab Biosimilar
  • U.S.FDA Approves Biocon Biologics' YESINTEK™, Bmab 1200 biosimilar to J&J's Stelara® (Ustekinumab)
  • Dr. Reddy's receives positive CHMP opinion from European Medicines Agency for its proposed Rituximab biosimilar
  • Zydus and Dr. Reddy's announce licensing agreement for co‐marketing of Pertuzumab biosimilar
  • EMA Approves Biocon Biologics' New mAbs Facility in India and Renews GMP Certifications for India and Malaysia Sites
  • Ipca Laboratories Ltd enters into technology transfer agreement with Omexa Formulary Pvt Ltd
  • CuraTeQ Biologics announces the successful Phase 1 clinical study outcome of their BP11 product
  • Biocon Biologics Secures Canada Market Entry Date for YESAFILI®, a Proposed Biosimilar to EYLEA®
  • CuraTeQ Biologics receives recommendation for grant of marketing authorization of 'biosimilar trastuzumab' from SEC operating under the aegis of CDSCO
  • Glenmark is the first to launch Biosimilar of Popular Anti‐Diabetic Drug, Liraglutide, in India
  • Biocon Biologics Receives European Commission Approval for YESAFILI®, Biosimilar Aflibercept
  • Biocon Biologics announces Positive CHMP Opinion for YESAFILI®, Biosimilar Aflibercept

Latest Post

  • Kolte-Patil Developers Ltd. Q4 & FY26 Financial Results
  • PNC Infratech Limited receives Rs. 228.90 crores based on settlement agreement from NHAI
  • NIS Management Ltd receives 5 work orders worth Rs. 30.77 crores
  • MAS Financial Services Ltd raises ₹360 Crore through NCD from FMO, the Dutch Entrepreneurial Development Bank
  • Aptus Pharma Ltd initiates brand promotion at Rajkot Hirasar Airport


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2025